[go: up one dir, main page]

KR890014097A - 리포좀 조성물 - Google Patents

리포좀 조성물 Download PDF

Info

Publication number
KR890014097A
KR890014097A KR1019890002699A KR890002699A KR890014097A KR 890014097 A KR890014097 A KR 890014097A KR 1019890002699 A KR1019890002699 A KR 1019890002699A KR 890002699 A KR890002699 A KR 890002699A KR 890014097 A KR890014097 A KR 890014097A
Authority
KR
South Korea
Prior art keywords
liposome
composition
liposome composition
osmotic pressure
drug
Prior art date
Application number
KR1019890002699A
Other languages
English (en)
Inventor
야스아끼 오가와
가쓰미 이가
야스따까 이가리
Original Assignee
우메모또요시마사
다께다 야꾸힝 고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우메모또요시마사, 다께다 야꾸힝 고오교 가부시끼가이샤 filed Critical 우메모또요시마사
Publication of KR890014097A publication Critical patent/KR890014097A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음.

Description

리포좀 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본 발명의 CDDP-함입(entrapping) 리포좀 조성물을 마우스에게 투여한후 관찰한 항종양 효과를 대조군과 비교하여 나타낸 도이다.

Claims (12)

  1. 약물 및 삼투압 조정제를 함유한 수용액이 함입(entrap)된 리포좀으로 이루어진 리포좀 조성물로서, 상기 리포좀이 40 내지 45℃의 상 전이온도를 갖는 막을 가지며, 상기 용액의 삼투압이 온혈동물의 체액의 삼투압보다 1.2배 내지 2.5배 높은 리포좀 조성물.
  2. 제 1항에 있어서, 리포좀 막의 주성분이 아실기가 포화 아실기인 인지질인 리포좀 조설물,
  3. 제 2항에 있어서, 인지질이 디팔미토일포스파티딜콜린과 디스테아로일포스파티딜콜린의 혼합물이며, 상기 디팔미토일포스파티딜 콜린 및 상기 디스테아로일포스파티딜 콜린의 비가 95/5 내지 70/30(중량비)인 리포좀 조성물.
  4. 제 1항에 있어서, 상 저이온도가 40 내지 43℃인 리포좀 조성물.
  5. 제 1항에 있어서, 약물이 항종양 제인 리포좀 조성물.
  6. 제 5항에 있어서, 항종양제가 시스플라틴인 리포좀 조성물.
  7. 제 1항에 있어서, 삼투압 조정제가 생리학적으로 허용되는 염, 당 또는 아미노산, 또는 이들의 혼합물인 리포좀 조성물.
  8. 제 1항에 있어서, 리포좀이 대형 단층 소포인 리포좀 조성물.
  9. 제 1항에 있어서, 약물이 시스플라틴이고, 삼투압 조정제가 염화나트륨과 만니톨의 혼합물이며, 리포좀은 그 막이 디팔미토일포그퍼티딜 콜린 및 디스테아로일포스파티딜 콜린으로 이루어져서 상 전이온도가 40 내지 43℃인 대형 단층 소포인 리포좀 조성물.
  10. 제 1항에 있어서, 주사제 형태의 리포좀 조성물.
  11. 발열 요법에 있어서 충실성 종양을 치료하기 위한 제 5항에 따른 리포좀 조성물의 용도.
  12. (1) 약물 및 삼투압 조정제가 함유된 수용액(여기서, 이 용액의 삼투압은 온혈동물의 체액보다 1.2 내지2.5배 높게 조정한다.)을 제조하고, (2) 생성된 수용액을 상 전이온도가 40 내지 45℃ 인 하나 이상의 인지질과 혼합하여 에멀젼을 제조하고, (3) 생성된 에멀젼에 리포좀 제조 공정을 행하여 리포좀 막의 상 전이온도가 40 내지 45℃이도록 하는 리포좀 조성물의 제조방법.
    ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019890002699A 1988-03-04 1989-03-04 리포좀 조성물 KR890014097A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5224988 1988-03-04
JP63-52249 1988-03-04

Publications (1)

Publication Number Publication Date
KR890014097A true KR890014097A (ko) 1989-10-21

Family

ID=12909460

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890002699A KR890014097A (ko) 1988-03-04 1989-03-04 리포좀 조성물

Country Status (6)

Country Link
US (1) US5094854A (ko)
EP (1) EP0331504B1 (ko)
KR (1) KR890014097A (ko)
AT (1) ATE77051T1 (ko)
CA (1) CA1335348C (ko)
DE (1) DE68901733T2 (ko)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5186941A (en) * 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
JPH04185601A (ja) * 1990-11-20 1992-07-02 Unitika Ltd 白金抗癌剤徐放性製剤
SE469043B (sv) * 1991-09-05 1993-05-03 Abb Carbon Ab Foerfarande och anordning foer varmhaallning av baeddmassa i pfbc-anlaeggningar
EP0551169A1 (en) * 1992-01-10 1993-07-14 Takeda Chemical Industries, Ltd. Liposome composition and production thereof
PT706373E (pt) * 1992-03-23 2000-11-30 Univ Georgetown Taxol encapsulado num liposoma e um metodo
CA2093381A1 (en) * 1992-04-07 1993-10-08 Hideyuki Sawahara Liposome formulation and process for production thereof
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US5810888A (en) 1997-06-26 1998-09-22 Massachusetts Institute Of Technology Thermodynamic adaptive phased array system for activating thermosensitive liposomes in targeted drug delivery
US6306432B1 (en) * 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
US6106858A (en) * 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
EP2308470A1 (en) 1997-09-18 2011-04-13 Pacira Pharmaceuticals, Inc. Sustained-release liposomal anesthetic compositions
ATE554748T1 (de) * 1997-11-14 2012-05-15 Pacira Pharmaceuticals Inc Herstellung von multivesikulären liposomen
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6461637B1 (en) * 2000-09-01 2002-10-08 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US7837720B2 (en) * 2000-06-20 2010-11-23 Boston Scientific Corporation Apparatus for treatment of tissue adjacent a bodily conduit with a gene or drug-coated compression balloon
US6958075B2 (en) * 2001-09-18 2005-10-25 Celsion Corporation Device and method for treatment of tissue adjacent a bodily conduit by thermocompression
CZ20031262A3 (en) * 2000-10-16 2004-03-17 Neopharm, Inc. Liposomal formulation of mitoxantrone
DE10107165A1 (de) * 2001-02-15 2002-08-29 Max Planck Gesellschaft Thermolabiles Liposom mit geregelter Freigabetemperatur
EP1424889A4 (en) * 2001-08-20 2008-04-02 Transave Inc PROCESS FOR TREATING LUNG CANCERS
US8709488B2 (en) 2002-02-14 2014-04-29 Gholam A. Peyman Method and composition for hyperthermally treating cells
US7964214B2 (en) * 2006-07-13 2011-06-21 Peyman Gholam A Method and composition for hyperthermally treating cells in the eye with simultaneous imaging
US8808268B2 (en) 2002-02-14 2014-08-19 Gholam A. Peyman Method and composition for hyperthermally treating cells
US8481082B2 (en) 2002-02-14 2013-07-09 Gholam A. Peyman Method and composition for hyperthermally treating cells
US8119165B2 (en) 2002-02-14 2012-02-21 Peyman Gholam A Method and composition for hyperthermally treating cells
US9017729B2 (en) 2002-02-14 2015-04-28 Gholam A. Peyman Method and composition for hyperthermally treating cells
US8932636B2 (en) 2002-02-14 2015-01-13 Gholam A. Peyman Method and composition for hyperthermally treating cells
US7101571B2 (en) * 2002-02-14 2006-09-05 Peyman Gholam A Method and composition for hyperthermally treating cells
US8137698B2 (en) * 2002-02-14 2012-03-20 Peyman Gholam A Method and composition for hyperthermally treating cells
US8795251B2 (en) 2002-02-14 2014-08-05 Gholam A. Peyman Method and composition for hyperthermally treating cells
US9320813B2 (en) 2002-02-14 2016-04-26 Gholam A. Peyman Method and composition for hyperthermally treating cells
US8668935B2 (en) 2002-02-14 2014-03-11 Gholam A. Peyman Method and composition for hyperthermally treating cells
US9302087B2 (en) 2002-02-14 2016-04-05 Gholam A. Peyman Method and composition for hyperthermally treating cells
US9393396B2 (en) 2002-02-14 2016-07-19 Gholam A. Peyman Method and composition for hyperthermally treating cells
US9289491B2 (en) 2002-02-14 2016-03-22 Gholam A. Peyman Method and composition for hyperthermally treating cells
US9233157B2 (en) 2002-02-14 2016-01-12 Gholam A. Peyman Method and composition for hyperthermally treating cells
US8801690B2 (en) 2002-02-14 2014-08-12 Gholam A. Peyman Method and composition for hyperthermally treating cells
CA2476078C (en) * 2002-02-15 2013-04-23 Celsion Corporation Method and apparatus treating tissue adjacent a bodily conduit with thermocompression and drugs
US20040101553A1 (en) * 2002-08-02 2004-05-27 Transave, Inc. Platinum aggregates and process for producing the same
US9186322B2 (en) 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
KR20040017002A (ko) * 2002-08-20 2004-02-26 한국화학연구원 삼투압유도제가 첨가된 국소이식형 항암제제
ES2831305T3 (es) 2002-10-29 2021-06-08 Insmed Inc Liposomas que comprenden un aminoglucósido para el tratamiento de infecciones pulmonares
JP4711947B2 (ja) * 2003-02-03 2011-06-29 ネオファーム、インコーポレイティッド 安定な濾過滅菌性リポソームに被包化されたタキサン及び他の抗腫瘍剤
US20080050425A1 (en) * 2003-05-20 2008-02-28 Jonathan Lewis Combination Chemotherapy Comprising 5-Fluorouracil or a Derivative Thereof and a Liposomal Platinum Complex
WO2004103344A1 (en) * 2003-05-20 2004-12-02 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
US20050107959A1 (en) * 2003-10-03 2005-05-19 Yuanpeng Zhang Screening method for evaluation of bilayer-drug interaction in liposomal compositions
AU2005223654A1 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
US7713517B2 (en) * 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
CN101001633A (zh) * 2004-05-21 2007-07-18 特兰萨夫公司 肺病和肺病前期病症的治疗
JP5176320B2 (ja) * 2004-08-11 2013-04-03 コニカミノルタエムジー株式会社 リポソーム含有製剤の製造方法
EP1811963A4 (en) * 2004-11-08 2010-01-06 Transave Inc METHOD FOR CREATING TREATMENT WITH INTRAPERITONEALLY APPLIED PLATINUM COMPOUND FORMULATIONS ON LIPID BASIS
US8765116B2 (en) 2005-03-24 2014-07-01 Medifocus, Inc. Apparatus and method for pre-conditioning/fixation and treatment of disease with heat activation/release with thermoactivated drugs and gene products
CN1913508B (zh) * 2005-08-08 2010-05-05 华为技术有限公司 基于正交频分复用的信号调制方法及其调制装置
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US7625757B2 (en) * 2006-01-27 2009-12-01 Sysmex Corporation Reagent for immature leukocyte analysis and reagent kit
US9119782B2 (en) 2006-03-20 2015-09-01 Mary P. McCourt Drug delivery means
US20110020428A1 (en) * 2007-11-15 2011-01-27 Qun Zeng Gel-stabilized liposome compositions, methods for their preparation and uses thereof
AU2008331764A1 (en) * 2007-12-05 2009-06-11 Marval Biosciences, Inc. Nano-scale contrast agents and methods of use
US20090311191A1 (en) * 2008-06-13 2009-12-17 Ananth Annapragada Imaging of atherosclerotic plaques using liposomal imaging agents
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
WO2011137514A1 (en) * 2010-05-03 2011-11-10 University Health Network Imageable activatable agent for radiation therapy and method and system for radiation therapy
EP2394640A1 (en) 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
EP2407157A1 (en) * 2010-07-13 2012-01-18 Koninklijke Philips Electronics N.V. Lipid bilayer carrier for drugs or imaging agents
ES2848025T3 (es) 2012-09-04 2021-08-05 Eleison Pharmaceuticals LLC Prevención de la recidiva pulmonar del cáncer con cisplatino complejado con lípidos
WO2014152795A2 (en) 2013-03-14 2014-09-25 Schentag Jerome J Cholestosome vesicles for incorporation of molecules into chylomicrons
US9855243B2 (en) * 2013-10-30 2018-01-02 Qurient Co., Ltd. Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation
WO2015166985A1 (ja) 2014-04-30 2015-11-05 富士フイルム株式会社 リポソーム組成物及びその製造方法
WO2015166987A1 (ja) 2014-04-30 2015-11-05 富士フイルム株式会社 リポソーム組成物及びその製造方法
HUE052968T2 (hu) 2014-04-30 2021-05-28 Fujifilm Corp Liposzóma kompozíció és annak elõállítási eljárása
JP6312226B2 (ja) 2014-08-11 2018-04-18 国立大学法人大阪大学 透析装置、リポソーム製造装置、及びリポソーム製造方法
MX381655B (es) 2015-05-04 2025-03-13 Versantis AG Metodo para preparar vesiculas con gradiente de ph de transmembrana.
EP3372223B1 (en) 2015-11-02 2024-04-17 FUJIFILM Corporation Liposome composition and method for producing same
US9849092B2 (en) 2015-12-21 2017-12-26 Gholam A. Peyman Early cancer detection and enhanced immunotherapy
US11090385B2 (en) 2015-12-21 2021-08-17 Gholam A. Peyman Early cancer detection and enhanced immunotherapy
US10300121B2 (en) 2015-12-21 2019-05-28 Gholam A. Peyman Early cancer detection and enhanced immunotherapy
US11433260B2 (en) 2015-12-21 2022-09-06 Gholam A. Peyman Cancer treatment methods using thermotherapy and/or enhanced immunotherapy
US11660229B2 (en) 2015-12-21 2023-05-30 Gholam A. Peyman Cancer treatment methods using thermotherapy and/or enhanced immunotherapy
US10136820B2 (en) 2015-12-21 2018-11-27 Gholam A. Peyman Method to visualize very early stage neoplasm or other lesions
US11419543B1 (en) 2016-03-03 2022-08-23 Gholam A. Peyman Early disease detection and therapy
US10376600B2 (en) 2016-03-03 2019-08-13 Gholam A. Peyman Early disease detection and therapy
EP3811949B1 (en) 2018-06-20 2024-07-03 FUJIFILM Corporation Combined medicine comprising gemcitabine-encapsulated liposome composition and immune checkpoint blockade
US11998765B2 (en) 2020-09-29 2024-06-04 Cancer Rx, LLC Cancer imaging methods and cancer treatment methods using thermotherapy and drug delivery
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251468B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12246092B1 (en) 2024-05-20 2025-03-11 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2103485B (en) * 1981-08-10 1986-04-03 Wellcone Foundation Limited Th Liposomes containing antimonyanti-leishmanaisis drugs
JPH0768117B2 (ja) * 1983-05-06 1995-07-26 ベスター・インコーポレイテツド 薬剤放出調整用小胞製剤
US4755388A (en) * 1984-11-09 1988-07-05 The Regents Of The University Of California Liposome-encapsulated 5-fluoropyrimidines and methods for their use
FR2586587B1 (fr) * 1985-08-30 1987-10-23 Adir Nouveaux surfactants artificiels, leur preparation et les compositions pharmaceutiques qui les contiennent.
ATE68968T1 (de) * 1985-11-22 1991-11-15 Takeda Chemical Industries Ltd Liposomzusammensetzung.

Also Published As

Publication number Publication date
EP0331504A1 (en) 1989-09-06
ATE77051T1 (de) 1992-06-15
CA1335348C (en) 1995-04-25
DE68901733D1 (de) 1992-07-16
DE68901733T2 (de) 1993-03-25
US5094854A (en) 1992-03-10
EP0331504B1 (en) 1992-06-10

Similar Documents

Publication Publication Date Title
KR890014097A (ko) 리포좀 조성물
EP0126751B2 (en) Method of preparing controlled-release preparations for biologically active materials
Jain et al. Proultraflexible lipid vesicles for effective transdermal delivery of levonorgestrel: development, characterization, and performance evaluation
JP2660839B2 (ja) 局所塗布用浸透促進製薬組成物
JPH06104622B2 (ja) リポソ−ム製剤の製造法
DE3485984T2 (de) Vesikelformulierungen zur kontrollierten abgabe der wirkstoffe.
GB1539625A (en) Process for preparing aqueous dispersions of lipid spherules and aqueous dispersions of such lipid spherules
KR880009636A (ko) 리포좀 조성물 및 그의 제조방법
CA2069760C (en) Lipid formulation system
CA1335349C (en) Liposome composition and its production
KR900701174A (ko) 인지질-함유 조성물, 이의 제조방법 및 이의 약제학적 물질용 부형제로서의 용도
JP2677576B2 (ja) 非水溶性の有効成分のためのリン脂質輪送ビヒクル
JPS59181224A (ja) 安定なインタ−フエロン製剤の製法
US4034114A (en) Treatment of skin keratoses with retinal
KR100343125B1 (ko) 도포용 리포좀형 혼합국소마취제 및 그 제조방법
Verma et al. Phosphatidylcholine: a revolution in drug delivery technology
Ammar et al. A transdermal delivery system for glipizide
Nagarsenker et al. Preparation, characterization, and evaluation of liposomal dispersions of lidocaine
JPH022850B2 (ko)
JP2931981B2 (ja) リポソーム製剤およびその製造法
JPH02250876A (ja) ２―フェニル―１，２―ベンズイソセレナゾール―３（２ｈ）―オンの安定した非経口溶液及びその製造方法
HU201873B (en) Process for producing lipide micromedium containing ibudilaste
Selye Prevention of cardiac necrosis by amiloride
WO1992006703A1 (en) Synthetic lung surfactant
DE69104294T2 (de) Arzneiformen, deren Herstellungsverfahren sowie deren Anwendungen.

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19890304

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid